Although initially responding to androgen deprivation therapy (ADT), cancer cells can adapt to ADT and restore AR signalling under low levels of androgens, and consequently, the disease progresses to more aggressive castration-resistant prostate cancer (CRPC) [8]. This evidence concerns the gene AR and cancer.